Seoul, May 21 (IANS) SK bioscience, a biotech arm of South Korea’s SK Group, on Wednesday said it has won a patent lawsuit against global pharmaceutical giant Pfizer over pneumococcal vaccine components.
In 2020, Pfizer filed a lawsuit with a Korean court, claiming that SK bioscience’s export of 13-valent pneumococcal conjugate vaccine (PCV13) components and finished products for research to Russia infringed on the composition patent of its vaccine Prevnar 13, Yonhap news agency.
South Korea’s Supreme Court recently upheld a lower court’s ruling that SK bioscience’s PCV13 components do not fall within the scope of Pfizer’s patent claims.
The court also ruled that the production and export of PCV13 products for research purposes do not constitute patent infringement.
SK bioscience developed SKYPneumo, South Korea’s first domestically produced PCV13, in 2016.
However, due to a separate patent dispute with Pfizer, the company remains restricted from manufacturing and selling the vaccine in South Korea until 2027, when the related patents are set to expire.
The company said the latest ruling is expected to open the door to exporting individual PCV13 components to countries with high vaccine demand, particularly in Southeast Asia and Latin America.
In parallel, SK bioscience is developing a 21-valent pneumococcal conjugate vaccine in collaboration with Sanofi S.A. The vaccine candidate entered global Phase 3 clinical trials in late 2024.
“This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds a new opportunity,” said SK bioscience Chief Executive Officer (CEO) Ahn Jae-yong.
“We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth,” Jae-yong added.
In April, SK bioscience also won a patent invalidation case against Moderna, the global developer of the messenger-RNA (mRNA) Covid-19 vaccine, Yonhap reported.
SK bioscience filed a nullity suit in 2023 challenging Moderna’s patent on modified nucleosides, nucleotides, and nucleic acids, as well as their uses, the company said.
Moderna’s patent is the only registered patent in South Korea related to mRNA manufacturing technology.
SK bioscience had argued the patent “unfairly granted priority rights, which hindered the development of mRNA technology.”
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
